Home Cart Sign in  
Chemical Structure| 144707-18-6 Chemical Structure| 144707-18-6

Structure of 2-D08
CAS No.: 144707-18-6

Chemical Structure| 144707-18-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

2-D08 is a cell-permeable small molecule inhibitor of SUMOylation that also inhibits Axl with an IC50 of 0.49 nM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of 2-D08

CAS No. :144707-18-6
Formula : C15H10O5
M.W : 270.24
SMILES Code : O=C1C=C(C2=CC=C(O)C(O)=C2O)OC3=C1C=CC=C3
MDL No. :MFCD27995567
InChI Key :JJAXTFSPCLZPIW-UHFFFAOYSA-N
Pubchem ID :22507438

Safety of 2-D08

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HCT116 cells 200 µM 24 hours The combination of 2-D08 with etoposide significantly enhanced apoptosis in HCT116 cells. PMC7311467
U251 cells 0-200 µM 24 hours 2-D08 significantly inhibited ZIKV replication, dose-dependent reduction of viral RNA load PMC6359730
Huh-7 cells 0-200 µM 24 hours 2-D08 significantly inhibited ZIKV replication, dose-dependent reduction of viral RNA load PMC6359730
SK-LMS-1 cells 0-100 µM 24 or 48 hours 2-D08 inhibited cell viability in a dose- and time-dependent manner and significantly inhibited the colony-forming ability of SK-LMS-1 cells. PMC11200159
SK-UT-1B cells 0-100 µM 24 or 48 hours 2-D08 slightly increased the apoptotic rate in SK-UT-1B cells but did not affect cell cycle progression. PMC11200159
16HBE cells 30 μM 6 hours To investigate the effect of 2-D08 on IL-13-induced ROCK2 phosphorylation, results showed that 2-D08 significantly reduced IL-13-induced ROCK2 phosphorylation PMC10314948
UACC-1598DM cells 30 µM 7 days Reduced SUMO1/2 expression, decreased DM counts, and lowered expression of DM-carried genes PMC10936631
Colo320DM cells 30 µM Decreased DM counts and lowered expression of DM-carried genes PMC10936631

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice OVA- or HDM-induced allergic asthma model intratracheal administration 10 or 30 mg/kg 2 hours after each OVA or HDM atomization, once daily for 7 days To investigate the effect of 2-D08 on allergic airway inflammation and goblet cell metaplasia, results showed that 2-D08 significantly attenuated OVA- or HDM-induced airway inflammation, hyperreactivity, and goblet cell metaplasia PMC10314948
Nude mice HCT116 xenograft model intraperitoneal injection 5 mg/kg every 2 days for 10 days The combination of 2-D08 with etoposide significantly inhibited tumor growth. PMC7311467
Mice Prostate cancer model IntratumOral injection 10 mg/kg Every 3 days for 2 weeks 2-D08 significantly suppressed tumor growth, reduced tumor mass, and increased tumor cell apoptosis. PMC9927932
Rats Spared Nerve Injury model Intrathecal injection 10, 30, 60, or 100 μM Once daily for 5 days 2-D08 significantly decreased the upregulation of UBC9 protein and SUMOylated Kir7.1 induced by SNI and increased the surface accumulation of Kir7.1 in the spinal cord. PMC9253747
SCID female mice UACC-1598DM xenograft model IntratumOral injection 10 mg/kg Every other day for 10 days Reduced tumor growth rate, decreased DM counts, and lowered expression of DM-carried genes PMC10936631

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.70mL

0.74mL

0.37mL

18.50mL

3.70mL

1.85mL

37.00mL

7.40mL

3.70mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories